Three pharmaceutical companies are killing 100,000 American diabetics annually. Greed is their weapon of choice. Eli Lilly, (Indiana) Novo Nordisk, (New Jersey,) and Sanofi, (Paris France,) control 99 percent of the insulin marketplace. There is no generic competitor to offer an alternative, or drive down prices. Unlike other industries, where competition might lead to price … Continue reading Could a Sick Bird Fly to Canada to Buy Insulin? →